Spots Global Cancer Trial Database for Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
Official Title: Phase II Trial of Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
Study ID: NCT04848337
Study Description
Brief Summary: Eligible patients will be treated with the combination of lenvatinib and pembrolizumab. A cycle equals 21 days and therapy will continue until radiographic progression, intolerable toxicity, or patient/physician wishes to discontinue protocol therapy. A maximum of 35 cycles may be administered. On Day 1, when both pembrolizumab and lenvatinib are administered, patients should take the lenvatinib per their normal routine.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
City of Hope, Duarte, California, United States
Winship Cancer Instituted of Emory University, Atlanta, Georgia, United States
University of Michigan Health System, Ann Arbor, Michigan, United States
Oregon health, Portland, Oregon, United States
Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Contact Details
Name: Ulka Vaishampayan, MD
Affiliation: University of Michigan
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
